Skip to main content
. 2017 Mar 17;71(7):e21967. doi: 10.1002/syn.21967

Figure 1.

Figure 1

Glucocerebrosidase (GCase) and β‐hexosaminidase (HEXB) activity after daily treatment with different levels of ambroxol. (a–d) GCase activity did not increase with 22.5 mg ambroxol treatment in any region, but increased by about 20% in the midbrain, cortex and striatum and 5% in the cerebellum with 100 mg treatment. (e‐h) HEXB activity was increased by about 20% in the midbrain, cortex, and striatum, but not in the cerebellum, when treated with 100 mg ambroxol